We are monitoring the impact of COVID-19 on Europe Oncology Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12280
Share on
Share on

Europe Oncology Drugs Market Research Report – Segmented By type, drug class, distribution channel, route of administration, drug classification & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12280
Pages: 125

Europe Oncology Drugs Market Size (2021 to 2026)

The Europe Oncology Drugs Market was worth USD 50.64 billion in 2021 and is estimated to be growing at a CAGR of 8.20%, to reach USD 75.11 billion by 2026.

Oncology helps study, diagnosis, and treatment of cancer. Cancer is a disease where abnormal cells grow uncontrollably and disrupt normal bodily functions. Oncology drugs act against both metastatic and benign cancers which may include bone marrow cancer, lung cancer, bone cancer, skin cancer, gastrointestinal cancer, breast cancer, oral cancer, and gynecological cancer, etc. 

The need for cancer treatments develops in tandem with the number of cancer diagnoses and deaths. Targeted therapy is becoming more popular as a cancer treatment. They offer several advantages over conventional therapies like chemotherapy and radiation. The many types of cancer medicines available are shown through a detailed analysis of the market by product category.

Additionally, medical research has received a lot of attention to reduce cancer incidence. As healthcare prices rise in different regions of the world, the industry is growing. As a result, the Europe oncology drugs market has been propelled forward by rising cancer incidence.

Cutting-edge cancer treatment technologies and techniques, as well as rising healthcare spending in developing nations, are likely to boost the European oncology drugs market forward. 

Moreover, regional pharmaceutical companies developing generic cancer treatments have formed strategic alliances to focus their efforts on developing high-efficacy generic oncology medicines. These strategic decisions have paid off handsomely for these companies, allowing them to retain market dominance in generic cancer medicines.

However, Chemotherapy medications attack cancer cells but also killing healthy cells in the body, resulting in a myriad of negative side effects for patients. Bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, weariness, and skin ailments are among the most common side effects. As a result, the market's expansion is constrained by cancer treatments' undesirable side effects.

Other factors limiting Europe oncology drugs market expansion during the projection period are stringent government regulations, high medical costs, and patient expiration. In most affluent countries, medical technology evaluation is becoming more common. Price management is a crucial problem in the oncology medicine industry, and financial risk-sharing agreements are frequently employed.

 The cost discrepancies between brand-name and generic medications are being investigated. To improve the local relevance of trials in European regulatory processes and shorten time to market, global studies are increasing patient enrollment. Internal product development activities should be integrated from the start, according to manufacturers.

This research report on the Europe oncology drugs market has been segmented and sub-segmented into the following categories:

By Type:

  • Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Brain Cancer
  • Thyroid Cancer
  • Skin Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Blood Cancer
  • Others

By Drug Class Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies/Drug Stores
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By Drug Classification:

  • Branded Drugs
  • Generic Drugs

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands and
  • Rest of Europe

The European oncology drugs market is projected to account a predominant share during the forecast period. Numerous multi-national organizations support cancer drugs, and the government increased a healthcare investment. However, Pharmaceutical treatments for cancer are becoming more effective. Even countries like Spain and France play a key role in oncology medication discovery and infrastructure development. In major countries, such as Germany, the United Kingdom, and Italy, lung cancer is the most common type of drug usage, whereas prostate cancer is the most common.  Spain and France have the largest geographical market share for cancer oncology medications. In the cancer oncology market, Spain and France have a major presence.

Germany dominated the Europe oncology drugs market and it is anticipated to continue its dominance during the forecast period. Presence of well-established healthcare infrastructure, increasing disposable income and supportive government policies are propelling the market growth. Other factors, such as cervical and liver cancers, are more frequent. Germany plays an important part in the procurement of anticancer prescription therapies in the region.

KEY MARKET PLAYERS:

F. Hoffmann-La Roche Ltd, Genentech, Inc., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, and Bayer AG are some of the notable companies in the European oncology drugs market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Europe Oncology drugs Market, By Type            

            6.2  Lung Cancer                    

            6.3   Pancreatic Cancer                      

            6.4 Breast Cancer                  

            6.5 Prostate Cancer               

            6.6 Ovarian Cancer                

            6.7    Colorectal Cancer                      

            6.8 Gastric Cancer                  

            6.9 Kidney Cancer                  

            6.10 Brain Cancer                  

            6.11 Brain Cancer                  

            6.12 Thyroid Cancer              

                        6.12.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.12.2 Y-o-Y Growth Rate Analysis    

                        6.12.3 Market Attractiveness Index  

            6.13 Europe Oncology drugs Market, By Drug Class Type:                

            6.14 Chemotherapy               

            6.15  Targeted Therapy                     

            6.16   Immunotherapy (Biologic Therapy)                 

            6.17  Hormonal Therapy                    

                        6.17.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.17.2 Y-o-Y Growth Rate Analysis    

                        6.17.1 Market Attractiveness Index  

            6.18 Europe Oncology drugs Market, By Distribution Channel:                     

            6.19 Hospital Pharmacies                  

            6.20  Retail Pharmacies/Drug Stores             

            6.21 Others                                                                

                        6.21.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.21.2 Y-o-Y Growth Rate Analysis    

                        6.21.3 Market Attractiveness Index  

            6.22 Europe Oncology drugs Market, By Route of Administration:               

            6.23  Oral                   

            6.24 Parenteral                      

            6.25 Others                   

                        6.25.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.25.2 Y-o-Y Growth Rate Analysis    

                        6.25.3 Market Attractiveness Index  

            6.26 Europe Oncology drugs Market, By Drug Classification:            

            6.27 Branded Drugs               

            6.28 Generic Drugs                       

                        6.28.1 Market Size Estimations & Forecasts (2021-2026)    

                        6.28.2 Y-o-Y Growth Rate Analysis    

                        6.28.3 Market Attractiveness Index  

7. Geographical Landscape                            

            7.1 Europe                 

                        7.1.1 By Country        

                                    7.1.1.1 UK

                                    7.1.1.2 France

                                    7.1.1.3 Germany

                                    7.1.1.4 Spain

                                    7.1.1.5 Italy

                                    7.1.1.6 Rest of Europe

                        7.1.2 By Type 

                        7.1.3  By Drug Class Type:     

                        7.1.4 By Distribution Channel:           

                        7.1.5 By Route of Administration:     

                        7.1.6 By Drug Classification:  

8. Key Player Analysis            

            8.1 Pfizer

8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

8.1.6 Analyst Overview

            8.2 Johnson & Johnson

            8.3 Novartis

            8.4 Bristol-Meyers Squibb Company

            8.5 AstraZeneca PLC

            8.6 F Hoffmann-La Roche Ltd

            8.7 Merck & Co

            8.8 AbbVie Inc.

            8.9 Astellas Pharma Inc.

            8.10 Amgen Inc.

9. Market Outlook & Investment Opportunities                               

10. Appendix                           

            List of Tables              

            List of Figures   

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of type, drug class type, distribution channel, route of administration, drug classification, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Europe Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  2. Europe Lung Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  3. Europe  Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  4. Europe  Breast Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  5. Europe   Prostate Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  6. Europe Ovarian Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  7. Europe   Colorectal Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  8. Europe Gastric Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  9. Europe Kidney Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  10. Europe  Brain Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  11. Europe   Thyroid Cancer Market, By Region, From 2021 to 2026 (USD Billion)

  12. Europe Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  13. Europe Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)

  14. Europe  Targeted Therapy Market, By Region, From 2021 to 2026 (USD Billion)

  15. Europe  Immunotherapy (Biologic Therapy) Market, By Region, From 2021 to 2026 (USD Billion)

  16. Europe  Hormonal Therapy Market, By Region, From 2021 to 2026 (USD Billion)

  17. Europe Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  18. Europe   Hospital Pharmacies Market, By Region, From 2021 to 2026 (USD Billion)

  19. Europe    Retail Pharmacies/Drug Stores Market, By Region, From 2021 to 2026 (USD Billion)

  20. Europe  Others Market, By Region, From 2021 to 2026 (USD Billion)

  21. Europe Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  22. Europe  Oral Market, By Region, From 2021 to 2026 (USD Billion)

  23. Europe Parenteral Market, By Region, From 2021 to 2026 (USD Billion)

  24. Europe Others Market, By Region, From 2021 to 2026 (USD Billion)

  25. Europe Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  26. Europe  Branded Drugs Market, By Region, From 2021 to 2026 (USD Billion)

  27. Europe   Generic Drugs Market, By Region, From 2021 to 2026 (USD Billion)

  28. U.K. Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  29. U.K. Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  30. U.K. Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  31. U.K. Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  32. U.K. Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  33. Germany Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  34. Germany Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  35. Germany Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  36. Germany Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  37. Germany Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  38. France Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  39. France Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  40. France Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  41. France Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  42. France Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  43. Italy Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  44. Italy Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  45. Italy Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  46. Italy Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  47. Italy Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

  48. Spain Global Oncology drugs Market, By Type, From 2021 to 2026 (USD Billion)

  49. Spain Global Oncology drugs Market, By Drug Class Type, From 2021 to 2026 (USD Billion)

  50. Spain Global Oncology drugs Market, By Distribution Channel, From 2021 to 2026 (USD Billion)

  51. Spain Global Oncology drugs Market, By Route of Administration, From 2021 to 2026 (USD Billion)

  52. Spain Global Oncology drugs Market, By Drug Classification, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample